Mirum set for AZURE-1 topline results Sept. 28
Mirum Pharmaceuticals said topline Phase 3 AZURE-1 results for brelovitug are due Sept. 28. The company also plans to report 48-week Phase 2b results and hold an investor call at 8:30 a.m. ET.
Mirum Pharmaceuticals said topline Phase 3 AZURE-1 results for brelovitug are due Sept. 28. The company also plans to report 48-week Phase 2b results and hold an investor call at 8:30 a.m. ET.